Section	Topics	Pages
	Abstract	1
1.	Introduction	3
2.	Neurotransmitter (NT) Reuptake Inhibitors	4
2.1.	Serotonin-Norepinephrine Reuptake Inhibitors	4
2.1.1.	Imipramine and Amitriptyline	4, 5
2.1.2	Clomipramine	6
2.1.3	Venlafaxine	6, 7
2.1.4.	Doxepin	7
2.2.	Selective Norepinephrine Reuptake Inhibitors	7
2.2.1	Maprotiline	7, 8
2.2.2.	Atomoxetine	8
2.3.	Selective Serotonin Reuptake Inhibitors	9
2.3.1.	Fluoxetine	9
2.3.2.	Citalopram/Escitalopram	9, 10
2.3.3.	Sertraline	10
2.3.4.	Fenfluramine	10, 11
3.	Dopaminergic, Serotonergic, Adrenergic and N-methyl-D-aspartate (NMDA) Receptor Blockers	11
3.1.	Loxapine/Amoxapine	11
3.2.	Clozapine	11, 12
3.3.	Mianserin	12
3.4.	Mirtazapine	12, 13
3.5.	Olanzapine	13
3.6.	Ketamine	14
3.7.	Chlorpromazine	14, 15
3.8.	Promazine	15
4.	Histamine-1 Receptor Antagonists	16
4.1.	Diphenhydramine	16
4.2.	Azelastine	16, 17
4.3.	Prometazine	17
5.	Opioid-mu-Receptor Agonists	17
5.1.	Morphine/Codeine	17, 18
5.2.	Tramadol	18
5.3.	Propoxyphene	19
5.4.	Meperidine	19
6.	Calcium-Channel Blockers	20
6.1.	Verapamil	20
6.2.	Diltiazem	20
6.3.	Amiodarone	21
7.	Drugs That Act at Sodiuzm Channels	21
7.1.	Local Anesthetics	21
7.1.1	Lidocaine	21
8.	Drugs That Act at GABAnergic Receptors	22
8.1.	Zopiclone	22
9.	Muscarinic-Receptor Blockers	22
9.1.	Tolterodine/Fesoterodine	22, 23
9.2.	Oxybutynin	23
10.	“If” Channel Blockers	23
10.1.	Ivabradine	23, 24
11.	Drugs That Act as Enzyme Inhibitors	24
11.1.	Sildenafil	24
12.	Drugs That Act on Microorganisms	24
12.1.	Chloroquine/Hydroxychloroquine	24–26
13.	Anticancer Drugs	26
13.1.	Imatinib	26
13.2.	Dacarbazine	26, 27
13.3.	Tamoxifen	27
13.4.	Tormifene	27, 28
14.	Metabolic N-dealkylation and N-oxidation	28
14.1.	Metabolic N-dealkylation	28, 29
14.1.1.	Focused N-dealkylation cases	30
14.1.1.1.	Loss of Pharmacologic Activity	30
14.1.1.2.	Modification of Receptor Inhibition Selectivity	30, 31
14.1.1.3.	Activation of Prodrugs	31
14.1.1.4.	Potential Drug Candidates (Metabolite Drugs)	31
14.2.	N-Oxidation Of Tertiary-Alkylamino-Moiety-Containing Drug	32
15.	Conclusions	33